5-Year Survival Data Showcases Long-Term Benefit With Nivolumab/Ipilimumab-Treated Metastatic NSCLC
June 12th 2022Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.